Your AI-Trained Oncology Knowledge Connection!

Alessio Fiascarelli

Articles by Alessio Fiascarelli

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH,Javier Cortés, MD,Francois Clement Bidard,Guillermo Streich,José García-Sáenz,Janice Lu, MD, PhD ,Giulia Tonini,Simona Scartoni,Alessandro Paoli,Alessio Fiascarelli,Alessandro Bressan,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

June 19th 2025

Latest Updated Articles

Trending on CancerNetwork

FDA Approves SC Pembrolizumab Formulation in Solid Tumors

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Isa-KRd Yields Significant MRD Negativity in High-Risk NDMM Cytogenetic Subgroups

CHMP Recommends Expanded Approval for 2 Pembrolizumab Indications

© 2025 MJH Life Sciences^®

All rights reserved.